Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
|Articles|April 1, 2003
It's back on the back: An itchy red rash
A 14-year-old girl is brought to you complaining of an itchy red rash on her back. The rash appeared four months ago as a scaly red bump and enlarged over several weeks in an annular pattern to cover a large area.
Advertisement
Advertisement
Related to this article
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Youth-onset type 2 diabetes may progress faster, signs easy to miss
2
FDA sets new PDUFA date for Anaphylm for type I allergic reactions
3
When one young athlete’s cardiac arrest revealed a family at risk
4
SUID drives widening Black-White infant mortality gap since 2020
5